Abcam plc (ABCZF)
Abcam plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, GB. The stock last traded at $22.25, up 0.68% on the session, giving a market capitalisation of $5.12B. On trailing twelve-month figures it carries a trailing P/E of 578.30, a net margin of 1.4%. Its beta of 0.86 implies it has historically moved less than the broad market.
Abcam plc is a prominent life sciences firm specializing in the creation, refinement, and provision of specialized agents and instruments crucial for scientific investigation, diagnostic procedures, and pharmaceutical development. Its diverse product portfolio primarily encompasses primary and secondary antibodies, along with conjugated antibodies and their respective conjugation kits. The company also offers singleplex and multiplex immunoassays, a variety of proteins and peptides (such as cytokines), and genetically modified cell lines and lysates. Additionally, their extensive catalog features other essential items like cellular activity kits, miRNA kits, various biochemical compounds, and tools designed for analyzing cell signaling pathways. Abcam caters to a wide clientele, including scientists and researchers at academic institutions and governmental research establishments, as well as professionals within the pharmaceutical, biotechnology, and diagnostics sectors. With a global footprint, the company maintains a presence across the Americas, Europe, the Middle East, Africa, China, Japan, and the broader Asia Pacific region. All its offerings are available for purchase directly via its online platform. Established in 1998, Abcam plc maintains its corporate headquarters in Cambridge, United Kingdom.
Abcam plc is most often compared with the following Healthcare names: